Good Afternoon Univec Conglomerate Investors. I often post

New Post Public Reply Private Reply Replies (1) Message Board
Kgem
1,317
Good Afternoon Univec Conglomerate Investors. I often post about the importance of high-grade processing and the state of the art in the cannabis industry, but there is one thing that fascinates me most, and it is the subject of CBD and nanotechnology.

The main reason being that I’ve learned so much more about the biological and chemical challenges of optimizing the bioavailability of cannabidiol (CBD). In other words, I’ve realized that the story isn’t about the efficacy and well-documented Cannabis science, it’s all about what CBD nanotechnology is bringing to Federal agencies and State and Local Taxing Authorities.

Trillions have been invested by big pharma in nano-science over the last three decades, but curiously little has been invested in delivery systems for drug medications --- until now. Hence, the interest in a CBD transdermal patch.

What is nanotechnology? Nanotechnology achieves the objective of manipulating atoms, molecules, and supramolecular formations and reducing their scale to between 1 and 100 nanometers (nm) according to the National Nanotechnology Initiative.

You can say that this means that our scientists are reducing particles and materials to one-millionth of their original size and even further.

Current examples of nanotechnology are now widespread including nano-medicine, biomaterials, microscopic devices, robots, computer chips, and essential organic compounds like CBD.

It wasn’t until the 80’s and the invention of scanning tunneling microscopes that we were able to actually see the nano-particles we were forming!

Today, scientists, physicians, and engineers are becoming very familiar with reducing the size of atoms, molecules… and yes, even physical devices to nanoscale. This is how they are realizing the enhanced properties of these particles and devices to achieve 100% bioavailability of organic phytonutrients like CBD compared to their original size counterparts.

No doubt about it. The primary trend in CBD manufacturing is nano-enhanced (nano-sized) cannabidiol (CBD). If you are a user of CBD hemp oil, you are probably well aware of this due to the number of new products increasing each month that “claim” to be incorporating nano-technology into their products and manufacturing.

The attractiveness and possibilities of nanotechnology and CBD began to take off after 2010. The reason for this is as follows:

• Creation of a 100% bioavailable delivery system for optimum effect
• Effective distribution throughout the body per dose
• Speed of delivery is significantly increased
* Better economies of scale in manufacturing – profit potential

Never before has nano-sized cannabidiol clusters been so stable in solution (water for example). And it is this development that has attracted the attention of the Federal Drug Administration (FDA) currently evaluating the efficacy of CBD nano-emulsification patented technologies.

In short, CBD nano-emulsified products will likely be the first FDA approved CBD products. And if that doesn’t excite you, then absolutely nothing will.

Creating pharmaceutical quality CBD products is about as high a bar a cannabis company can set for itself. And this is the clear objective with respect to a number of patents pending current review by the FDA. CBD companies and lab facilities are also applying for FDA Authorized Lab approvals and licenses which would be a CBD industry first.

Consumers expect product homogeneity, high quality, safety, and nano CBD products must be stabilized and duplicable. Otherwise, these products will not the meet strict homogeneity criteria required by the FDA and consumers alike.
Strict manufacturing standards and guidance for the human pharmaceutical industry is provided by the “Current Good Manufacturing Practice” regulations (CGMP). Further guidance for the industry includes “Packaging, Labeling, or Holding Operations for Dietary Supplements.”

Few people are aware of CGMPs, and how the FDA’s mandate to assure drug manufacturing standards, practices, and processes are changing the industry.

A word of caution. What I can discern from my own research is that the term “nano-enhanced hemp oil” can only be taken at face value. I find it difficult to find substantial proof online from most manufacturers. And from what I read in the highest ranked blog posts on the subject, I am amazed at the in-your-face inaccuracies and misinformation contained in them. I’ve found that most manufacturers are simply replicating well-established lyposomal, colloidal and/or micelle technologies and using standardized equipment. Nothing really new, and of course every company will argue that “theirs” is better than another due to their chemical and procedural approaches.

The problem with nano CBD product manufacturing is that CBD is very difficult to work with. Quite different than adding CBD isolate to oil, and then placing an attractive label on it. Many of product websites make the most ignorant statements and claims from a biochemistry standpoint and thereby reveal their shortcomings and lack of scientific value. Thus, buyer beware.
Simply put, not all nano CBD products are created equal.

REFERENCES:


https://www.ncbi.nlm.nih.gov/pubmed/16304818
https://www.nano.gov/nanotech-101/what/definition
https://www.fda.gov/Drugs/DevelopmentApproval...169105.htm
http://blog.sonomechanics.com/blog/ultrasonic...nnabinoids
https://www.prnewswire.com/news-releases/cbd-...21169.html
http://eng.thesaurus.rusnano.com/wiki/article1199
https://www.genome.gov/27532724/epigenomics-fact-sheet/
https://becomingasuperhuman.com/nootropics-bi...en-fowkes/


Kgem




1

Univec Conglomerate Inc (UNVC) Stock Research Links

UNVC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading